CRSP should give an update on their in vivo CAR-T approach in the next few months. The lead program is transient, re-dosable using engineered (m)RNA with an extended half-life. The second is site-specific integration using next-generation editing including HDR- and HITI-based integration, retrotransposons. Both will be delivered by a proprietary antibody-LNP platform.
Market Data 
Markets 
AI
